Orchestra BioMed Holdings (OBIO) Research & Development (2022 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Research & Development of $15.8 million for Q1 2026, up 17.05% year-over-year from $13.5 million in Q1 2025, and down 6.19% quarter-over-quarter from $16.8 million in Q4 2025.
Orchestra BioMed Holdings (OBIO) Research & Development (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Research & Development for 5 consecutive years, with $15.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 17.05% year-over-year to $15.8 million; the TTM figure through Mar 2026 stood at $60.5 million (up 28.21% YoY), while the FY2025 annual figure was $58.2 million, up 35.93% from the prior year.
- Research & Development eased to $15.8 million in Q1 2026 per OBIO's latest filing, from $16.8 million in the prior quarter.
- Across five years, Research & Development topped out at $16.8 million in Q4 2025 and bottomed at $3.5 million in Q1 2022.
- Historically, Research & Development has averaged $10.1 million across 5 years, with a median of $9.1 million in 2024.
- Annual changes were most pronounced in 2023 — Research & Development surged 137.59% — and 2024, when it gained 10.39%.
- Orchestra BioMed Holdings' Research & Development stood at $7.5 million in 2022, then advanced by 12.83% to $8.5 million in 2023, then advanced by 28.9% to $11.0 million in 2024, then jumped by 53.34% to $16.8 million in 2025, then fell by 6.19% to $15.8 million in 2026.
- Business Quant data shows OBIO's Research & Development at $15.8 million in Q1 2026, $16.8 million in Q4 2025, and $14.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Orchestra BioMed Holdings | 265.06 Mn | 80.63 Mn | 63,000.00 | 16.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.59 Mn |
| Mar 31, 2026 | 15.78 Mn |
| Dec 31, 2025 | 16.82 Mn |
| Sep 30, 2025 | 14.03 Mn |
| Jun 30, 2025 | 13.85 Mn |
| Mar 31, 2025 | 13.48 Mn |
| Dec 31, 2024 | 10.97 Mn |
| Sep 30, 2024 | 11.60 Mn |
| Jun 30, 2024 | 11.13 Mn |
| Mar 31, 2024 | 9.11 Mn |
| Dec 31, 2023 | 8.51 Mn |
| Sep 30, 2023 | 8.56 Mn |
| Jun 30, 2023 | 8.50 Mn |
| Mar 31, 2023 | 8.25 Mn |
| Dec 31, 2022 | 7.54 Mn |
| Sep 30, 2022 | 5.90 Mn |
| Jun 30, 2022 | 5.03 Mn |
| Mar 31, 2022 | 3.47 Mn |